US 10604582
Anti-CD276 antibodies (B7H3)
granted A61KA61K2039/505A61K2300/00
Quick answer
US patent 10604582 (Anti-CD276 antibodies (B7H3)) held by The United States of America, as represented by the Secretary, Department of Health expires Mon Mar 26 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- The United States of America, as represented by the Secretary, Department of Health
- Grant date
- Tue Mar 31 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Mar 26 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 37
- CPC classes
- A61K, A61K2039/505, A61K2300/00, A61K39/39558, A61K47/68031